Duhao Net helps individual entrepreneurs and enterprises find high-quality suppliers, reduce procurement costs, and make transactions easier.

Hubei Jianxiang Biopharmaceutical Co., Ltd.: CGMP Peptide supplier

Release time：2024-09-30 20:30:00 Source：DuHao

Tel : +86-0715-8310333

Email: net.fei@163.com

Address: No. 9, Lvshan Road, Xianning City, Hubei Province, China

Hubei Jianxiang Biopharmaceutical Co., Ltd. (hereinafter referred to as Hubei Jianxiang) is a high-tech biopharmaceutical enterprise specializing in the research, development, production, and sales of peptide-based products. Established in 2015, the company is strategically located in the Xianning Economic Development Zone, Hubei Province, covering more than 600 acres, with 300 acres allocated for the first phase of its development. Hubei Jianxiang operates as a subsidiary of Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. (Jianyuan Pharmaceutical), a national high-tech enterprise focused on peptide research and innovation.

Production Facilities & Capacity

Hubei Jianxiang's state-of-the-art facilities are designed to meet the cGMP (current Good Manufacturing Practice) standards of the United States, the European Union, and China. The company initiated construction in 2016 and aimed to commence production by the end of 2018. The first phase of development saw the establishment of 16 peptide Active Pharmaceutical Ingredient (API) production lines, with a total investment of 3 billion yuan. Each production line has a designed capacity of 150 kg, contributing to a total production capacity of 2,400 kg annually.

The company's production facilities also include auxiliary infrastructure such as warehousing, inspection systems, and environmental protection mechanisms, ensuring high-quality output. Hubei Jianxiang has already built eight peptide API production lines and plans to expand further with new production lines and facilities. With a workforce expected to grow from 270 to over 350 employees in 2024, the company is poised for continuous growth.

Main Products & Services

Hubei Jianxiang focuses on a wide range of peptide-related products, including:

Peptide APIs for pharmaceuticals
Peptide drug preparations
Contract Research Organization (CRO) & Contract Manufacturing Organization (CMO) services for peptide products
Peptides for food and cosmetics
Peptides for veterinary use

These products are supplied to major domestic pharmaceutical manufacturers, research institutions, and international markets, catering to a diverse clientele. Hubei Jianxiang’s peptide APIs are highly sought after, particularly in overseas pharmaceutical markets.

Research & Development

Hubei Jianxiang has a strong emphasis on innovation, with its parent company, Jianyuan Pharmaceutical, leading in the development of peptide drugs, prodrugs, and sustained-release microspheres for peptides and proteins. The company has a robust R&D platform for new peptide drug development, with proprietary intellectual property rights and innovative technologies. These advancements have enabled the industrialization of peptide drug research and the development of next-generation pharmaceuticals.

Economic Impact & Future Growth

With the completion of the first phase, Hubei Jianxiang aims to significantly expand its business scale, industrialize its R&D results, and achieve economies of scale. The project is expected to generate an annual sales revenue of 8 billion yuan and create more than 800 jobs, contributing to the region’s economic and social development. The company’s innovative efforts are not only aimed at economic gains but also at generating environmental and social benefits.

In addition to peptide production, the company is constructing a raw material pharmaceutical industry park that meets the CGMP requirements of the European Union, the United States, and China. Once fully operational, the company anticipates achieving an annual GDP of 5 billion yuan and paying 500 million yuan in taxes.

Market Performance & Future Prospects

In recent years, Hubei Jianxiang has demonstrated remarkable growth. In 2020, the company’s sales revenue exceeded 30 million yuan, and with the international market's continued expansion, sales reached 140 million yuan between January and August 2023. The company's deputy general manager, Long Lei, expressed confidence that sales revenue would reach 230 million yuan by the end of 2023. During peak holiday periods, the company's production facilities remained operational to meet the growing demand for customized peptide products.

Looking ahead, Hubei Jianxiang plans to increase production capacity and workforce steadily, with 2024 expected to see an expansion to 350 employees. The peptide industry is known for its high investment requirements and long development cycles, but Hubei Jianxiang is well-prepared for future opportunities and challenges, with strong momentum and confidence in its continued success.

In summary, Hubei Jianxiang Biopharmaceutical Co., Ltd. is a forward-thinking enterprise with cutting-edge technology, a growing market presence, and a commitment to advancing the peptide industry. With its innovative approach, extensive production capabilities, and strong leadership, the company is positioned to become a leading player both domestically and internationally in the peptide pharmaceutical industry.

Duhao Net